Missing BsUFA Revenue Trigger Could Open US FDA Staff To Criminal Penalty
Staffing Cuts At FDA Could Threaten Ability To Collect Biosimilar User Fees
Massive layoffs and the biosimilar user fee program’s historic flirtation with the non-user fee spending requirements raise concerns that the FDA could lose its ability to collect BsUFA revenue, which could mean a fine or jail time for agency staff.
